{"id":9054,"date":"2022-02-10T12:52:00","date_gmt":"2022-02-10T11:52:00","guid":{"rendered":"https:\/\/czecrin.cz\/project\/kh-discovery\/"},"modified":"2026-01-06T10:00:49","modified_gmt":"2026-01-06T09:00:49","slug":"kh-discovery","status":"publish","type":"project","link":"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/","title":{"rendered":"KH DisCoVeRy"},"content":{"rendered":"\n<h3 class=\"wp-block-heading has-text-align-center\">CLINICAL TRIALS DISCoVeRy<\/h3>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-black-color has-alpha-channel-opacity has-black-background-color has-background\"\/>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center\">A multicenter, adaptive, randomized study of the safety and efficacy of treatment in hospitalized adult patients with COVID-19.<\/p>\n\n\n\n<p class=\"has-text-align-center\">The treatment of COVID-19 is still a major challenge for medical research, so new drugs are being investigated or the use of existing drugs is being optimized. One of the new medicines is a cocktail of two monoclonal antibodies developed by AstraZeneca. The DisCoVeRy clinical trial aims to evaluate the efficacy and safety of different therapeutics compared to a control group. A total of 1260 patients are planned to be enrolled in the study. The sponsor of the multicentre clinical trial is the French National Institute for Health and Medical Research, which is implementing the study in three centres in the Czech Republic through VI CZECRIN.    <\/p>\n\n\n\n<h6 class=\"wp-block-heading has-text-align-center\">OVERVIEW OF RECRUITMENT<\/h6>\n\n\n\n<p class=\"has-text-align-center\">Based on the decision of the Discovery Steering Committee, recruitment into the study was completed as of July 1, 2022, with a total of 237 patients enrolled. No patients were enrolled in the Czech Republic and the clinical trial was not initiated.  <\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center\">Important project links and documents<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td class=\"has-text-align-center\" data-align=\"center\"><strong><a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000936-23\/CZ\" target=\"_blank\" rel=\"noreferrer noopener\">EU Clinical Trials Register<\/a><\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315948?term=discovery&amp;recrs=a&amp;type=Intr&amp;cond=%22COVID-19%22&amp;phase=2&amp;fund=3&amp;draw=2&amp;rank=1\" target=\"_blank\" rel=\"noreferrer noopener\">KH registration on Clinicaltrials.gov<\/a><\/strong><\/td><\/tr><tr><td class=\"has-text-align-center\" data-align=\"center\"><strong><a href=\"https:\/\/eu-response.eu\/faq\/#1614759574453-872afad7-8d7b\" target=\"_blank\" rel=\"noreferrer noopener\">Official project website<\/a><\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong><a href=\"https:\/\/czecrin.cz\/wp-content\/uploads\/2025\/04\/Initial-opinion-FN-Brno.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Approval of KH MEK FN Brno<\/a><\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading has-text-align-center\">Contact<\/h5>\n\n\n\n<p class=\"has-text-align-center has-medium-font-size\">Study sponsor:<br>INSERM | <a href=\"mailto:eu-response@inserm.fr\">eu-response@inserm.fr<\/a><\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center has-medium-font-size\">Project Manager:<br>Ing. Karol\u00edna Grodov\u00e1 | <a href=\"mailto:karolina.grodova@med.muni.cz\">karolina.grodova@med.muni.cz<\/a><\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<ul class=\"wp-block-social-links is-content-justification-center is-layout-flex wp-container-core-social-links-is-layout-16018d1d wp-block-social-links-is-layout-flex\"><li class=\"wp-social-link wp-social-link-x  wp-block-social-link\"><a href=\"https:\/\/twitter.com\/intent\/tweet?hashtags=remed%2Cczecrin%2Cclinicaltrials&#038;original_referer=https%3A%2F%2Fczecrin.cz%2F&#038;ref_src=twsrc%5Etfw%7Ctwcamp%5Ebuttonembed%7Ctwterm%5Eshare%7Ctwgr%5E&#038;related=%40czecrin&#038;text=KH%20DisCoVeRy%20-%20Czecrin&#038;url=https%3A%2F%2Fczecrin.cz%2Fprojekty%2Fkh-discovery%2F\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M13.982 10.622 20.54 3h-1.554l-5.693 6.618L8.745 3H3.5l6.876 10.007L3.5 21h1.554l6.012-6.989L15.868 21h5.245l-7.131-10.378Zm-2.128 2.474-.697-.997-5.543-7.93H8l4.474 6.4.697.996 5.815 8.318h-2.387l-4.745-6.787Z\" \/><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">X<\/span><\/a><\/li><\/ul>\n","protected":false},"excerpt":{"rendered":"<p>CLINICAL TRIALS DISCoVeRy A multicenter, adaptive, randomized study of the safety and efficacy of treatment in hospitalized adult patients with COVID-19. The treatment of COVID-19 is still a major challenge for medical research, so new drugs are being investigated or the use of existing drugs is being optimized. One of the new medicines is a [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"project_category":[163,164],"project_tag":[161,165,166],"class_list":["post-9054","project","type-project","status-publish","hentry","project_category-completed-clinical-trials","project_category-thematic-clinical-trial-projects","project_tag-immunology","project_tag-infectious-diseases","project_tag-platform-adaptive-clinical-trial"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KH DisCoVeRy &#8226; CZECRIN - \u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu<\/title>\n<meta name=\"description\" content=\"Effect of dexamethasone in patients with ARDS and COVID-19 - a prospective, multicentre, open-label, randomised controlled trial with parallel groups.COVID-19 is still a major challenge for medical research, with new drugs or possible optimisation of existing drugs being investigated. One possibility to use an existing drug is treatment with the corticosteroid dexamethasone. The REMED clinical trial is designed to test the hypothesis that administration of 20 mg dexamethasone daily is more effective compared to a daily dose of 6 mg dexamethasone in adult patients with moderate or severe ARDS related to COVID-19. The initiator of this multicentre study is the University Hospital Brno - Department of Anaesthesiology, Resuscitation and Intensive Medicine, which in collaboration with VI CZECRIN is conducting the study in 10 centres in the Czech Republic in 300 patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KH DisCoVeRy &#8226; CZECRIN - \u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu\" \/>\n<meta property=\"og:description\" content=\"Effect of dexamethasone in patients with ARDS and COVID-19 - a prospective, multicentre, open-label, randomised controlled trial with parallel groups.COVID-19 is still a major challenge for medical research, with new drugs or possible optimisation of existing drugs being investigated. One possibility to use an existing drug is treatment with the corticosteroid dexamethasone. The REMED clinical trial is designed to test the hypothesis that administration of 20 mg dexamethasone daily is more effective compared to a daily dose of 6 mg dexamethasone in adult patients with moderate or severe ARDS related to COVID-19. The initiator of this multicentre study is the University Hospital Brno - Department of Anaesthesiology, Resuscitation and Intensive Medicine, which in collaboration with VI CZECRIN is conducting the study in 10 centres in the Czech Republic in 300 patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/\" \/>\n<meta property=\"og:site_name\" content=\"CZECRIN - \u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/czecrin\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-06T09:00:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/czecrin.cz\/wp-content\/uploads\/2025\/02\/czecrin__zakladni-logo-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1733\" \/>\n\t<meta property=\"og:image:height\" content=\"952\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/\",\"url\":\"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/\",\"name\":\"KH DisCoVeRy &#8226; CZECRIN - \u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu\",\"isPartOf\":{\"@id\":\"https:\/\/czecrin.cz\/en\/#website\"},\"datePublished\":\"2022-02-10T11:52:00+00:00\",\"dateModified\":\"2026-01-06T09:00:49+00:00\",\"description\":\"Effect of dexamethasone in patients with ARDS and COVID-19 - a prospective, multicentre, open-label, randomised controlled trial with parallel groups.COVID-19 is still a major challenge for medical research, with new drugs or possible optimisation of existing drugs being investigated. One possibility to use an existing drug is treatment with the corticosteroid dexamethasone. The REMED clinical trial is designed to test the hypothesis that administration of 20 mg dexamethasone daily is more effective compared to a daily dose of 6 mg dexamethasone in adult patients with moderate or severe ARDS related to COVID-19. The initiator of this multicentre study is the University Hospital Brno - Department of Anaesthesiology, Resuscitation and Intensive Medicine, which in collaboration with VI CZECRIN is conducting the study in 10 centres in the Czech Republic in 300 patients.\",\"breadcrumb\":{\"@id\":\"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Dom\u016f\",\"item\":\"https:\/\/czecrin.cz\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Projects\",\"item\":\"https:\/\/czecrin.cz\/en\/project\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"KH DisCoVeRy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/czecrin.cz\/en\/#website\",\"url\":\"https:\/\/czecrin.cz\/en\/\",\"name\":\"CZECRIN\",\"description\":\"\u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu\",\"publisher\":{\"@id\":\"https:\/\/czecrin.cz\/en\/#organization\"},\"alternateName\":\"\u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/czecrin.cz\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/czecrin.cz\/en\/#organization\",\"name\":\"VVI CZECRIN\",\"alternateName\":\"\u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu\",\"url\":\"https:\/\/czecrin.cz\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/czecrin.cz\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/czecrin.cz\/wp-content\/uploads\/2025\/02\/czecrin__zakladni-logo-1.png\",\"contentUrl\":\"https:\/\/czecrin.cz\/wp-content\/uploads\/2025\/02\/czecrin__zakladni-logo-1.png\",\"width\":1733,\"height\":952,\"caption\":\"VVI CZECRIN\"},\"image\":{\"@id\":\"https:\/\/czecrin.cz\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/czecrin\",\"https:\/\/www.linkedin.com\/company\/czecrin\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KH DisCoVeRy &#8226; CZECRIN - \u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu","description":"Effect of dexamethasone in patients with ARDS and COVID-19 - a prospective, multicentre, open-label, randomised controlled trial with parallel groups.COVID-19 is still a major challenge for medical research, with new drugs or possible optimisation of existing drugs being investigated. One possibility to use an existing drug is treatment with the corticosteroid dexamethasone. The REMED clinical trial is designed to test the hypothesis that administration of 20 mg dexamethasone daily is more effective compared to a daily dose of 6 mg dexamethasone in adult patients with moderate or severe ARDS related to COVID-19. The initiator of this multicentre study is the University Hospital Brno - Department of Anaesthesiology, Resuscitation and Intensive Medicine, which in collaboration with VI CZECRIN is conducting the study in 10 centres in the Czech Republic in 300 patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/","og_locale":"en_US","og_type":"article","og_title":"KH DisCoVeRy &#8226; CZECRIN - \u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu","og_description":"Effect of dexamethasone in patients with ARDS and COVID-19 - a prospective, multicentre, open-label, randomised controlled trial with parallel groups.COVID-19 is still a major challenge for medical research, with new drugs or possible optimisation of existing drugs being investigated. One possibility to use an existing drug is treatment with the corticosteroid dexamethasone. The REMED clinical trial is designed to test the hypothesis that administration of 20 mg dexamethasone daily is more effective compared to a daily dose of 6 mg dexamethasone in adult patients with moderate or severe ARDS related to COVID-19. The initiator of this multicentre study is the University Hospital Brno - Department of Anaesthesiology, Resuscitation and Intensive Medicine, which in collaboration with VI CZECRIN is conducting the study in 10 centres in the Czech Republic in 300 patients.","og_url":"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/","og_site_name":"CZECRIN - \u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu","article_publisher":"https:\/\/www.facebook.com\/czecrin","article_modified_time":"2026-01-06T09:00:49+00:00","og_image":[{"width":1733,"height":952,"url":"https:\/\/czecrin.cz\/wp-content\/uploads\/2025\/02\/czecrin__zakladni-logo-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/","url":"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/","name":"KH DisCoVeRy &#8226; CZECRIN - \u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu","isPartOf":{"@id":"https:\/\/czecrin.cz\/en\/#website"},"datePublished":"2022-02-10T11:52:00+00:00","dateModified":"2026-01-06T09:00:49+00:00","description":"Effect of dexamethasone in patients with ARDS and COVID-19 - a prospective, multicentre, open-label, randomised controlled trial with parallel groups.COVID-19 is still a major challenge for medical research, with new drugs or possible optimisation of existing drugs being investigated. One possibility to use an existing drug is treatment with the corticosteroid dexamethasone. The REMED clinical trial is designed to test the hypothesis that administration of 20 mg dexamethasone daily is more effective compared to a daily dose of 6 mg dexamethasone in adult patients with moderate or severe ARDS related to COVID-19. The initiator of this multicentre study is the University Hospital Brno - Department of Anaesthesiology, Resuscitation and Intensive Medicine, which in collaboration with VI CZECRIN is conducting the study in 10 centres in the Czech Republic in 300 patients.","breadcrumb":{"@id":"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/czecrin.cz\/en\/project\/kh-discovery\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/czecrin.cz\/en\/project\/kh-discovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Dom\u016f","item":"https:\/\/czecrin.cz\/en\/"},{"@type":"ListItem","position":2,"name":"Projects","item":"https:\/\/czecrin.cz\/en\/project\/"},{"@type":"ListItem","position":3,"name":"KH DisCoVeRy"}]},{"@type":"WebSite","@id":"https:\/\/czecrin.cz\/en\/#website","url":"https:\/\/czecrin.cz\/en\/","name":"CZECRIN","description":"\u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu","publisher":{"@id":"https:\/\/czecrin.cz\/en\/#organization"},"alternateName":"\u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/czecrin.cz\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/czecrin.cz\/en\/#organization","name":"VVI CZECRIN","alternateName":"\u010cesk\u00e1 n\u00e1rodn\u00ed s\u00ed\u0165 pro podporu klinick\u00e9ho v\u00fdzkumu","url":"https:\/\/czecrin.cz\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/czecrin.cz\/en\/#\/schema\/logo\/image\/","url":"https:\/\/czecrin.cz\/wp-content\/uploads\/2025\/02\/czecrin__zakladni-logo-1.png","contentUrl":"https:\/\/czecrin.cz\/wp-content\/uploads\/2025\/02\/czecrin__zakladni-logo-1.png","width":1733,"height":952,"caption":"VVI CZECRIN"},"image":{"@id":"https:\/\/czecrin.cz\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/czecrin","https:\/\/www.linkedin.com\/company\/czecrin\/"]}]}},"_links":{"self":[{"href":"https:\/\/czecrin.cz\/en\/wp-json\/wp\/v2\/project\/9054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/czecrin.cz\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/czecrin.cz\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/czecrin.cz\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/czecrin.cz\/en\/wp-json\/wp\/v2\/comments?post=9054"}],"version-history":[{"count":3,"href":"https:\/\/czecrin.cz\/en\/wp-json\/wp\/v2\/project\/9054\/revisions"}],"predecessor-version":[{"id":11373,"href":"https:\/\/czecrin.cz\/en\/wp-json\/wp\/v2\/project\/9054\/revisions\/11373"}],"wp:attachment":[{"href":"https:\/\/czecrin.cz\/en\/wp-json\/wp\/v2\/media?parent=9054"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/czecrin.cz\/en\/wp-json\/wp\/v2\/project_category?post=9054"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/czecrin.cz\/en\/wp-json\/wp\/v2\/project_tag?post=9054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}